Trial Profile
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 14 Nov 2016 New trial record